Adaptive Biotechnologies
Adaptive Biotechnologies makes clonoSEQ, the FDA-cleared sequencing test that finds one leukaemia cell in a million and now guides treatment in ALL, myeloma, and CLL.
clonoSEQ (IGH/IGK/IGL and TCR clonotype NGS) was the first FDA-cleared NGS MRD test (2018, ALL and myeloma; CLL 2020); used as the MRD endpoint in E1910-style and myeloma trials and in routine practice; blood-based monitoring in CLL and myeloma. Also immune medicine (T-Detect).
Pages like this
not linked directly; found by shared links- TechnologyMultiparameter flow cytometry MRD
Shares Dormant cells and minimal residual disease, Chronic lymphocytic leukaemia, MRD / molecular residual disease testing, Multiple myeloma.
- CompanyForesight Diagnostics
Shares Reference materials and open proficiency testing for residual disease tests, Dormant cells and minimal residual disease, MRD / molecular residual disease testing.
- IdeaA watch-and-wait registry for blood precursor conditions found by chance
- IdeaMRD-guided treatment-free intervals in myeloma
Shares Dormant cells and minimal residual disease, MRD / molecular residual disease testing, Multiple myeloma.
- InstitutionGIMEMA
Shares Chronic lymphocytic leukaemia, MRD / molecular residual disease testing, Multiple myeloma, Acute lymphoblastic leukaemia.
- TermMRD-negative complete remission
Shares NGS-based MRD (clonoSEQ and molecular MRD), Dormant cells and minimal residual disease, Chronic lymphocytic leukaemia, MRD / molecular residual disease testing.
- CompanyNatera
Shares Reference materials and open proficiency testing for residual disease tests, Dormant cells and minimal residual disease, MRD / molecular residual disease testing.
- TermFlow cytometry (immunophenotyping)
Shares Chronic lymphocytic leukaemia, Multiple myeloma, Acute lymphoblastic leukaemia.